BioCentury
ARTICLE | Company News

Biotest acquiring Nabi's biologics unit

September 12, 2007 2:33 AM UTC

Biotest (FSE:BIO) will acquire NABI's Nabi Biologics group for $185 million in cash. BIO said the group complements its European plasma protein business and gives it a presence in the U.S. immunoglobulin market.

BIO gets Nabi's Nabi-HB hepatitis B immune globulin, which is approved to prevent HBV infection upon acute exposure to the virus and had 2006 sales of $32.7 million and 1H07 sales of $18.8 million. BIO also will receive NABI's plasma protein production plant, nine U.S. plasma collection centers and NABI's headquarters in Boca Raton, Fla. BIO has Cytotect, a hyperimmunoglobulin against cytomegalovirus (CMV) that is marketed in some European countries to treat CMV infection during organ transplantation. This quarter, BIO and partner Abbott (ABT) plan to begin a Phase III trial of Cytotect to treat CMV infection during pregnancy. ...